Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 May-Jun;88(3):471-480.
doi: 10.1016/j.bjorl.2021.03.003. Epub 2021 Apr 3.

Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil

Wilma T Anselmo-Lima  1 , Edwin Tamashiro  1 , Fabrizio R Romano  2 , Marcel M Miyake  3 , Renato Roithmann  4 , Eduardo M Kosugi  5 , Márcio Nakanishi  6 , Marco A Fornazieri  7 , Thiago F P Bezerra  8 , João F Mello Jr  9 , Marcus M Lessa  10 , Richard L Voegels  9 , Otávio B Piltcher  11 , Eulalia Sakano  12 , Fabiana C P Valera  13
Affiliations
Review

Guideline for the use of immunobiologicals in chronic rhinosinusitis with nasal polyps (CRSwNP) in Brazil

Wilma T Anselmo-Lima et al. Braz J Otorhinolaryngol. 2022 May-Jun.

Abstract

Introduction: Severe uncontrolled chronic rhinosinusitis with nasal polyps has a negative impact on an individual's quality of life. Therefore, new biologics have emerged for use in specific phenotypes of chronic rhinosinusitis, changing the paradigms of its treatment.

Objective: To review the current status of biologic treatment indications in chronic rhinosinusitis.

Methods: The Brazilian Academy of Rhinology brought together different specialists to suggest a course of action, considering its particularities and aspects related to the national reality.

Results: Of particular interest for decision making will be the identification of subgroups of patients refractory to pre-existing treatment options and the construction of a strategy that improves their quality of life, with the best cost-benefit ratio.

Conclusion: The use of biologics is a valid option for treatment in more severe cases. This strategy must be better understood and improved in the future, with more studies and greater clinical experience.

Keywords: Chronic rhinosinusitis; Immunobiologicals; Monoclonal antibody; Nasal polyps.

PubMed Disclaimer

References

    1. Fokkens W.J., Lund V.J., Hopkins C., Hellings P.W., Kern R., Reitsma S., et al. European Position Paper on Rhinosinusitis and Nasal Polyps 2020. Rhinology. 2020;58:1–464. - PubMed
    1. DeConde A.S., Mace J.C., Levy J.M., Rudmik L., Alt J.A., Smith T.L. Prevalence of polyp recurrence after endoscopic sinus surgery for chronic rhinosinusitis with nasal polyposis. Laryngoscope. 2017;127:550–555. - PMC - PubMed
    1. Damask C.C., Ryan M.W., Casale T.B., Castro M., Franzese C.B., Lee S.E., et al. Targeted Molecular Therapies in Allergy and Rhinology. Otolaryngol Head Neck Surg. 2021;164:S1–S21. - PubMed
    1. Gandhi N.A., Bennett B.L., Graham N.M., Pirozzi G., Stahl N., Yancopoulos G.D. Targeting key proximal drivers of type-2 inflammation in disease. Nat Rev Drug Discov. 2016;15:35–50. - PubMed
    1. Laidlaw T.M., Buchheit K.M. Biologics in chronic rhinosinusitis with nasal polyposis. Ann Allergy Asthma Immunol. 2020;124:326–332. - PMC - PubMed

Substances